The NHS-Galleri trial is the first and only randomized controlled study of an MCED test. It evaluated annual screening with the Galleri test alongside standard of care over three years in individuals aged 50 to 77. Topline results announced in February 2026 had already pointed to a substantial reduction in Stage IV cancer diagnoses. The full dataset to be presented at ASCO will provide a more complete picture of the test's population-level impact.
The PATHFINDER 2 study, conducted in North America, builds on initial results presented in October 2025. It is the largest interventional study of an MCED test in its intended-use population—asymptomatic individuals with an elevated risk for cancer, such as those aged 50 or older.
The Galleri test is a prescription-based blood test intended to be used in addition to existing single-cancer screening methods like mammograms and colonoscopies. By detecting a common cancer signal across more than 50 cancer types and predicting the signal's origin, the test aims to find cancers earlier when they are more treatable.
The upcoming presentations are critical for GRAIL. Strong results from these large-scale, rigorous trials would provide a powerful evidence base to support the clinical utility and performance of Galleri, potentially accelerating its integration into standard medical practice and supporting reimbursement discussions with payers. Investors will be closely watching the ASCO presentations between May 29 and June 2 for the detailed efficacy and safety data.
This article is for informational purposes only and does not constitute investment advice.
